Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation (NASDAQ: NEOG) provides essential solutions for food safety and animal health through advanced diagnostic technologies. This page serves as the definitive source for official company news, offering investors and industry professionals timely updates on developments impacting global food security and veterinary practices.
Access curated press releases and announcements covering financial results, product launches, strategic partnerships, and regulatory milestones. Our aggregation ensures you stay informed about NEOG's innovations in pathogen detection, molecular testing platforms, and biosafety initiatives without needing to monitor multiple sources.
All content is verified for accuracy and relevance, providing a trustworthy resource for understanding Neogen's market position and technological advancements. Key updates include progress in genomic testing, international expansion efforts, and collaborations with agricultural regulators.
Bookmark this page or check back regularly for unfiltered access to Neogen's corporate communications and critical updates that shape the future of food and animal safety industries.
Neogen (NASDAQ: NEOG) has launched Igenity BCHF, a groundbreaking genomic test designed to assess the genetic risk of Bovine Congestive Heart Failure (BCHF) in cattle. The test provides a 1-to-10 scoring system, where 1 indicates the lowest risk and 10 the highest risk of disease development, with each score decrease representing approximately 3.5% lower expected incidence rate.
The innovative test aims to help producers manage BCHF risk within their herds, produce lower-risk feeder calves, and reduce economic losses. BCHF is identified as a significant threat affecting both young calves on pasture and late-fed cattle. According to Dr. Victor Pedrosa, Director of Technical Genomics and Innovation, the test results indicate the percentage of BCHF risk an animal might pass to its progeny.
Neogen (NASDAQ: NEOG) has launched a new quantitative Salmonella molecular detection assay, MDA2QSAL96. This innovative product combines qualitative pathogen testing with Quantitative Rapid Enrichment Dehydrated (QRED) media, specifically designed for poultry producers to verify intervention effectiveness.
The new assay offers enhanced consistency and sensitivity for poultry rinses and ground poultry meat testing, featuring an efficient workflow that optimizes time and resources. It joins Neogen's suite of next-generation assays on their Molecular Detection System platform, which utilizes isothermal DNA amplification and bioluminescence detection technology.
Notably, the USDA Food Safety and Inspection Service has designated Neogen's Molecular Detection System as the primary method for detecting various pathogens, including Salmonella, Listeria monocytogenes, and Listeria spp. The system is currently utilized in over 40 countries by food processors, universities, governments, and testing laboratories.
Neogen (NEOG) reported preliminary Q2 2025 results with revenue of $231.3 million, up 0.7% year-over-year. The company posted a net loss of $456.3 million ($(2.10) per share), primarily due to a non-cash goodwill impairment charge related to the former 3M Food Safety Division acquisition. Adjusted Net Income was $24.4 million ($0.11 per share).
The Food Safety segment revenue decreased 0.1% to $164.2 million, while Animal Safety segment revenue increased 2.8% to $67.0 million. Core revenue growth was 3.5%, excluding currency impacts and acquisitions. The company updated its full-year guidance, now expecting revenue between $905-925 million and Adjusted EBITDA of $205-215 million, citing U.S. dollar strengthening and operational challenges.
The company identified material weaknesses in internal controls and expects to file its Form 10-Q by January 15, 2025.
Neogen (NASDAQ: NEOG) has announced its participation in two major upcoming investor conferences in January 2025. The company will first attend the CJS Securities 25th Annual Investor Conference, which will be held virtually on January 14, 2025.
Following this, John Adent, Neogen's President and CEO, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025, at 3:45 PM PT. Investors can access the webcast and presentation materials for the J.P. Morgan Healthcare Conference through the Events & Presentations section of Neogen's Investor Relations website.
Neogen (NASDAQ: NEOG) has announced a change to its second-quarter earnings release date due to U.S. equity markets being closed for the National Day of Mourning for former U.S. President Jimmy Carter. The company will now release its second-quarter earnings before market opening on Friday, January 10, 2025.
Company executives will host a webcast and conference call at 8:00 a.m. Eastern time to discuss the financial results. The call can be accessed via phone at (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international). A replay will be available after the call through Neogen's Investor Relations website.
Neogen (NASDAQ: NEOG) has announced it will release its second-quarter earnings before market opening on Thursday, January 9, 2025. The company will host a webcast and conference call at 8:00 a.m. Eastern time to discuss the financial results. Investors can access the call via phone at (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international). A live webcast will be available through Neogen's Investor Relations webpage. A replay of both the call and webcast will be accessible afterward using specific dial-in numbers and entry code 39384#.
Neogen (NASDAQ: NEOG) has launched the Petrifilm Bacillus cereus Count Plate, a new food safety testing solution. The innovative product provides a simplified method for detecting Bacillus cereus bacteria, delivering results in as few as 20 hours. The ready-to-use plate tests for the entire sensu lato groups, including B. cytotoxicus, while eliminating traditional agar method prep work.
The product enhances Neogen's established Petrifilm line, which has been trusted in microbial testing for over 40 years. This launch aims to address critical food safety needs with improved efficiency and reliability in laboratory testing protocols.
Neogen (NASDAQ: NEOG) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The event will take place on Wednesday, December 4, 2024, featuring a presentation by John Adent, Neogen's President and CEO, at 11:00 a.m. Eastern Time. The presentation and webcast materials will be accessible through the Events & Presentations section of Neogen's Investor Relations website.
Neogen (NASDAQ: NEOG) has announced its participation in the 2024 UBS Global Healthcare Conference. The event will take place on Tuesday, November 12, in Rancho Palos Verdes, California. This participation represents an opportunity for Neogen to engage with healthcare industry stakeholders and investors at a significant industry event.
Neogen (NASDAQ: NEOG) announced its first-quarter results for fiscal year 2025, ending August 31, 2024. The company reported revenue of $217.0 million, a 5.3% decrease from the previous year. Neogen experienced a net loss of $12.6 million, or $(0.06) per diluted share, compared to a net income of $1.5 million in the prior year. Adjusted Net Income was $14.4 million, or $0.07 per diluted share, while Adjusted EBITDA reached $43.7 million.
The Food Safety segment saw a 4.2% decrease in revenue to $159.3 million, while the Animal Safety segment experienced an 8.1% decline to $57.6 million. Despite challenges, Neogen is maintaining its full-year guidance, expecting revenue between $925 million and $955 million, with Adjusted EBITDA ranging from $215 million to $235 million.
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
